Harvest Medicine Surpasses 15,000 Patient Milestone in under 18 Months of Operation
June 19 2018 - 7:00AM
ABcann Global Corporation (TSX-V:ABCN)
(“
ABcann”) is pleased to announce that its
wholly-owned subsidiary, Harvest Medicine Inc. (“
Harvest
Medicine” or “
HMed”), one of Canada’s
fastest growing specialty medical cannabis clinics, has surpassed
15,000 active patients, reaching this significant milestone in
under 18 months of operation. Harvest Medicine is poised to take
its education focused model across Canada, through the opening of
new locations and the launch of a purpose-built telemedicine
app.
“Our rapid growth is a testament to our
patient-centric approach and dedication to providing exceptional
care,” stated Shekhar Parmar, Chief Executive Officer of HMed. “We
partner with patients to empower them to be more involved in their
healthcare and ensure that they receive the safest and most
effective medical cannabis treatment for their individualized
needs.”
With the opening of a new location in the
Edmonton area planned for July, and launch of the telemedicine app
expected by the end of the summer, Harvest Medicine is expecting
strong continued growth.
“Our vision is to transform the medical cannabis
experience for patients and physicians and be recognized as the
trusted leader in medical cannabis care across the country,” said
Mr. Parmar.
According to Health Canada statistics, the
number of registered medical cannabis patients continues to grow
dramatically across Canada. At the end of December 2017, there were
269,502 registered medical cannabis patients, a growth of over 54%
since April 2017 and over 579% since December 2015.
Demonstrating its commitment to being a leader
in the medical market, ABcann acquired Harvest Medicine in January
2018. The insights gained from Harvest Medicine regarding patient
experiences, needs, required products and desire for greater
guidance inspired ABcann to develop a specialty medical brand:
Beacon Medical. Beacon will be a recognized producer
of standardized pharma-grade cannabis products that HMed patients
will be able to access, together with products of other Licensed
Producers.
For more information about Harvest Medicine,
visit hmed.ca.
About Harvest Medicine
Harvest Medicine, a wholly-owned subsidiary of
ABcann Global Corporation (TSX-V:ABCN), is an education focused,
patient-centric, cannabis discovery center and clinic that has
received tremendous response from its patients. Growing to over
15,000 active patients in under 18 months, HMed is one of Canada’s
most successful and fastest growing cannabis clinics. Harvest
Medicine is poised to aggressively expand its effective and highly
scalable model across the country. Using a highly trained team of
medical doctors and Canna Genius educators, Harvest Medicine
provides a welcoming environment that focuses on empowering and
educating patients on the safe, effective use of medical
cannabis. HMED.ca provides patients clear explanations of the
medical cannabis process as well as additional educational
resources such as strain reviews, Licensed Producer reviews,
success stories, and accessory recommendations.
About ABcann:
ABcann is recognized for high-quality, trusted
products and services. It holds production and sales licenses from
Health Canada, and its flagship facility in Napanee, Ontario
contains proprietary plant-growing technology, centred on its
specially designed, environmentally-controlled growing chambers.
This approach results in the production of pharmaceutical-grade
cannabis products. ABcann is expanding its production capacity and
pursuing partnership and product development opportunities
domestically, as well as in select international markets, such as
Germany, Australia and Israel.
For more information about Harvest Medicine,
please contact:
Shekhar Parmar at sp@hmed.ca
For more information about ABcann, please
contact:
Barry Fishman at barry.fishman@abcannglobal.com or Michael Bumby
at michael.bumby@abcannglobal.com
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Disclaimer for Forward-Looking
Information
Certain statements in this news release are
forward-looking statements, which are statements that are not
purely historical, including statements regarding the beliefs,
plans, expectations or intentions of ABcann and its management
regarding the future. Forward looking statements in this news
release include statements relating to: the expected timing of
opening of the Edmonton HMed clinic; the expected timing of launch
of the HMed telemedicine app; HMed’s expectation of strong
continued growth; HMed’s vision to transform the medical cannabis
experience for patients and be recognized as a trusted leader in
medical cannabis care; and that HMed is poised to aggressively
expand its effective and highly scalable model across Canada. Such
statements are subject to risks and uncertainties that may cause
actual results, performance or developments to differ materially
from those contained in the forward-looking statements, including:
(i) that there may be delays in the opening of the Edmonton clinic
or launch of the telemedicine app; (ii) that the demand for medical
cannabis may decrease following the launch of Canada’s legal adult
use cannabis market, which may slow or reduce HMed’s expansion
abilities; (iii) changes to applicable governmental regulations
that impede HMed’s operations; (iv) that HMed’s business model may
not be scalable as expected or may not be accepted in jurisdictions
outside of Alberta; and (v) other factors beyond the Company’s
control. No assurance can be given that any of the events
anticipated by the forward-looking statements will occur or, if
they do occur, what benefits ABcann or HMed will obtain from them.
Readers are urged to consider these factors, and the more extensive
risk factors included in ABcann’s annual information form dated
April 30, 2018, which is available on SEDAR, carefully in
evaluating the forward-looking statements contained in this news
release, and are cautioned not to place undue reliance on such
forward-looking statements, which are qualified in their entirety
by these cautionary statements. The forward-looking statements in
this news release are made as of the date hereof and ABcann
disclaims any intent or obligation to update publicly any such
forward-looking statements, whether as a result of new information,
future events or results or otherwise, except as required by
applicable securities laws.
Abcann Global Corporation (TSXV:ABCN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abcann Global Corporation (TSXV:ABCN)
Historical Stock Chart
From Apr 2023 to Apr 2024